Hanna, Daire and Merrick, Sophie and Ghose, Aruni and Devlin, Michael John and Yang, Dorothy D. and Phillips, Edward and Okines, Alicia and Chopra, Neha and Papadimatraki, Elisavet and ROSS, KIRSTY and MacPherson, Iain and Boh, Zhuang Y. and Michie, Caroline O. and Swampillai, Angela and Gupta, Sunnia and Robinson, Tim and Germain, Lewis and Twelves, Chris and Atkinson, Charlotte and Konstantis, Apostolos and Riddle, Pippa and Cresti, Nicola and Naik, Jay D. and Borley, Annabel and Guppy, Amy and Schmid, Peter and Phillips, Melissa (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130 (12). pp. 1916-1920. ISSN 0007-0920

<img xmlns="http://www.w3.org/1999/xhtml" src="https://pub.demo35.eprints-hosting.org/221/2.haslightboxThumbnailVersion/325023.pdf" class="document_preview_tile_thumbnail"/> <span xmlns="http://www.w3.org/1999/xhtml" title="325023.pdf">325023.pdf</span>
325023.pdf - Published Version
Available under License Creative Commons Attribution.

Download (421kB)
Abstract

Background:
Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.

Methods:
Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG.

Results:
132 pts were included. Median age was 56 years (28–91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5–6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts.

Conclusion:
This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.

Information
Title Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
Creators Hanna, Daire and Merrick, Sophie and Ghose, Aruni and Devlin, Michael John and Yang, Dorothy D. and Phillips, Edward and Okines, Alicia and Chopra, Neha and Papadimatraki, Elisavet and ROSS, KIRSTY and MacPherson, Iain and Boh, Zhuang Y. and Michie, Caroline O. and Swampillai, Angela and Gupta, Sunnia and Robinson, Tim and Germain, Lewis and Twelves, Chris and Atkinson, Charlotte and Konstantis, Apostolos and Riddle, Pippa and Cresti, Nicola and Naik, Jay D. and Borley, Annabel and Guppy, Amy and Schmid, Peter and Phillips, Melissa
Identification Number 10.1038/s41416-024-02685-9
Date 29 June 2024
Divisions College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher Nature Publishing Group
Library
URI https://pub.demo35.eprints-hosting.org/id/eprint/221
Item Type Article
Depositing User Unnamed user with email ejo1f20@soton.ac.uk
Date Deposited 11 Jun 2025 16:36
Revision 14
Last Modified 12 Jun 2025 10:45
View Item